Jounce Therapeutics Inc JNCE:NASDAQ

Last Price$3.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change-0.01(0.33%)
Bid (Size)$2.50 (2)
Ask (Size)$3.80 (5)
Day Low / High$2.87 - 3.11
Volume289.7 K
 

View Biotechnology IndustryPeer Comparison as of 06/30/2022

 

Jounce Therapeutics Inc ( NASDAQ )

Price: $3.03
Change: -0.01 (0.33%)
Volume: 289.7 K
4:00PM ET 6/30/2022
 
 

Personalis Inc ( NASDAQ )

Price: $3.45
Change: -0.04 (1.15%)
Volume: 449.7 K
4:00PM ET 6/30/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

INmune Bio Inc ( NASDAQ )

Price: $8.84
Change: -0.13 (1.45%)
Volume: 188.1 K
4:00PM ET 6/30/2022
 
 

Precision BioSciences Inc ( NASDAQ )

Price: $1.60
Change: +0.04 (2.56%)
Volume: 6.0 M
4:00PM ET 6/30/2022
 

Read more news Recent News

Piper Sandler Lowers Jounce Therapeutics' Price Target to $9 From $17, Maintains Overweight Rating
9:56AM ET 5/23/2022 MT Newswires

Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $7 to $20, according to analysts polled by Capital IQ. (MT...

Jounce Therapeutics' Shares Drop After Baird Downgrade
2:10PM ET 5/11/2022 MT Newswires

Shares of Jounce Therapeutics (JNCE) were down almost 19% in Wednesday afternoon trading after Baird downgraded the clinical-stage drugmaker's stock to...

--Baird Downgrades Jounce Therapeutics to Neutral From Outperform, Adjusts Price Target to $7 From $15
7:23AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Raymond James Upgrades Jounce Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $20 From $15
8:02AM ET 5/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. View company web site for more details
Address780 Memorial Drive
Cambridge, Massachusetts 02139
Phone+1.857.259.3840
Number of Employees115
Recent SEC Filing06/28/20224
President, Chief Executive Officer & DirectorRichard Murray
Chief Financial Officer & TreasurerKimberlee Cobleigh Drapkin
Chief Medical OfficerElizabeth G. Trehu
Chief Scientific OfficerDmitri Wiederschain

Company Highlights

Price Open$3.02
Previous Close$3.04
52 Week Range$2.76 - 9.81
Market Capitalization$156.6 M
Shares Outstanding51.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.98
Beta vs. S&P 500N/A
Revenue$65.2 M
Net Profit Margin-400.91%
Return on Equity-43.16%

Analyst Ratings as of 06/08/2022

Buy
5
Overweight
0
Hold
2
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset